164 related articles for article (PubMed ID: 29700386)
1. Minimal residual disease analysis in chronic lymphocytic leukemia: a way for achieving more personalized treatments.
Ghia P; Rawstron A
Leukemia; 2018 Jun; 32(6):1307-1316. PubMed ID: 29700386
[TBL] [Abstract][Full Text] [Related]
2. Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial.
Böttcher S; Ritgen M; Fischer K; Stilgenbauer S; Busch RM; Fingerle-Rowson G; Fink AM; Bühler A; Zenz T; Wenger MK; Mendila M; Wendtner CM; Eichhorst BF; Döhner H; Hallek MJ; Kneba M
J Clin Oncol; 2012 Mar; 30(9):980-8. PubMed ID: 22331940
[TBL] [Abstract][Full Text] [Related]
3. A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study.
Rawstron AC; Fazi C; Agathangelidis A; Villamor N; Letestu R; Nomdedeu J; Palacio C; Stehlikova O; Kreuzer KA; Liptrot S; O'Brien D; de Tute RM; Marinov I; Hauwel M; Spacek M; Dobber J; Kater AP; Gambell P; Soosapilla A; Lozanski G; Brachtl G; Lin K; Boysen J; Hanson C; Jorgensen JL; Stetler-Stevenson M; Yuan C; Broome HE; Rassenti L; Craig F; Delgado J; Moreno C; Bosch F; Egle A; Doubek M; Pospisilova S; Mulligan S; Westerman D; Sanders CM; Emerson R; Robins HS; Kirsch I; Shanafelt T; Pettitt A; Kipps TJ; Wierda WG; Cymbalista F; Hallek M; Hillmen P; Montserrat E; Ghia P
Leukemia; 2016 Apr; 30(4):929-36. PubMed ID: 26639181
[TBL] [Abstract][Full Text] [Related]
4. Minimal Residual Disease Assessment Improves Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia (CLL) Who Achieve Partial Response: Comprehensive Analysis of Two Phase III Studies of the German CLL Study Group.
Kovacs G; Robrecht S; Fink AM; Bahlo J; Cramer P; von Tresckow J; Maurer C; Langerbeins P; Fingerle-Rowson G; Ritgen M; Kneba M; Döhner H; Stilgenbauer S; Klapper W; Wendtner CM; Fischer K; Hallek M; Eichhorst B; Böttcher S
J Clin Oncol; 2016 Nov; 34(31):3758-3765. PubMed ID: 27573660
[TBL] [Abstract][Full Text] [Related]
5. Optimization and Validation of an 8-Color Single-Tube Assay for the Sensitive Detection of Minimal Residual Disease in B-Cell Chronic Lymphocytic Leukemia Detected via Flow Cytometry.
Dowling AK; Liptrot SD; O'Brien D; Vandenberghe E
Lab Med; 2016 May; 47(2):103-11. PubMed ID: 27069028
[TBL] [Abstract][Full Text] [Related]
6. Measurable Residual Disease in Chronic Lymphocytic Leukemia: Current Understanding and Evolving Role in Clinical Practice.
Rios-Olais FA; Hilal T
Curr Treat Options Oncol; 2023 Aug; 24(8):907-928. PubMed ID: 37195588
[TBL] [Abstract][Full Text] [Related]
7. Use of minimal residual disease assessment in the treatment of chronic lymphocytic leukemia.
Owen C; Christofides A; Johnson N; Lawrence T; MacDonald D; Ward C
Leuk Lymphoma; 2017 Dec; 58(12):2777-2785. PubMed ID: 28509580
[TBL] [Abstract][Full Text] [Related]
8. Minimal residual disease monitoring in chronic lymphocytic leukaemia patients. A comparative analysis of flow cytometry and ASO IgH RQ-PCR.
Raponi S; Della Starza I; De Propris MS; Del Giudice I; Mauro FR; Marinelli M; Di Maio V; Piciocchi A; Foà R; Guarini A
Br J Haematol; 2014 Aug; 166(3):360-8. PubMed ID: 24735016
[TBL] [Abstract][Full Text] [Related]
9. Improving efficiency and sensitivity: European Research Initiative in CLL (ERIC) update on the international harmonised approach for flow cytometric residual disease monitoring in CLL.
Rawstron AC; Böttcher S; Letestu R; Villamor N; Fazi C; Kartsios H; de Tute RM; Shingles J; Ritgen M; Moreno C; Lin K; Pettitt AR; Kneba M; Montserrat E; Cymbalista F; Hallek M; Hillmen P; Ghia P;
Leukemia; 2013 Jan; 27(1):142-9. PubMed ID: 23041722
[TBL] [Abstract][Full Text] [Related]
10. Minimal residual disease in chronic lymphocytic leukaemia.
García Vela JA; García Marco JA
Med Clin (Barc); 2018 Feb; 150(4):144-149. PubMed ID: 28864095
[TBL] [Abstract][Full Text] [Related]
11. Minimal residual disease in chronic lymphocytic leukemia: A consensus paper that presents the clinical impact of the presently available laboratory approaches.
Tomuleasa C; Selicean C; Cismas S; Jurj A; Marian M; Dima D; Pasca S; Petrushev B; Moisoiu V; Micu WT; Vischer A; Arifeen K; Selicean S; Zdrenghea M; Bumbea H; Tanase A; Grewal R; Pop L; Aanei C; Berindan-Neagoe I
Crit Rev Clin Lab Sci; 2018 Aug; 55(5):329-345. PubMed ID: 29801428
[TBL] [Abstract][Full Text] [Related]
12. The evolving use of minimal residual disease (MRD) assessment in chronic lymphocytic leukemia.
Cheson BD; Mato AR
Clin Adv Hematol Oncol; 2020 Jun; 18 Suppl 10(6):1-20. PubMed ID: 33843867
[TBL] [Abstract][Full Text] [Related]
13. A look into the future: can minimal residual disease guide therapy and predict prognosis in chronic lymphocytic leukemia?
Ghia P
Hematology Am Soc Hematol Educ Program; 2012; 2012():97-104. PubMed ID: 23233566
[TBL] [Abstract][Full Text] [Related]
14. Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival.
Moreton P; Kennedy B; Lucas G; Leach M; Rassam SM; Haynes A; Tighe J; Oscier D; Fegan C; Rawstron A; Hillmen P
J Clin Oncol; 2005 May; 23(13):2971-9. PubMed ID: 15738539
[TBL] [Abstract][Full Text] [Related]
15. [Minimal residual disease in chronic lymphocytic leukemia: A still current issue in 2018].
Gauthier M; Comont T; Vergez F; Ysebaert L
Bull Cancer; 2018 Nov; 105(11):1042-1051. PubMed ID: 30243477
[TBL] [Abstract][Full Text] [Related]
16. Eradication of minimal residual disease with alemtuzumab in B-cell chronic lymphocytic leukemia (B-CLL) patients: the need for a standard method of detection and the potential impact of bone marrow clearance on disease outcome.
Montillo M; Schinkoethe T; Elter T
Cancer Invest; 2005; 23(6):488-96. PubMed ID: 16203656
[TBL] [Abstract][Full Text] [Related]
17. Beyond detectable minimal residual disease in chronic lymphocytic leukemia.
Hillmen P
Semin Oncol; 2006 Apr; 33(2 Suppl 5):S23-8. PubMed ID: 16720200
[TBL] [Abstract][Full Text] [Related]
18. Flow cytometry minimal residual disease after allogeneic transplant for chronic lymphocytic leukemia.
Algrin C; Golmard JL; Michallet M; Reman O; Huynh A; Perrot A; Sirvent A; Plesa A; Salaun V; Béné MC; Bories D; Tournilhac O; Merle-Béral H; Leblond V; Le Garff-Tavernier M; Dhedin N
Eur J Haematol; 2017 Apr; 98(4):363-370. PubMed ID: 27943415
[TBL] [Abstract][Full Text] [Related]
19. Is MRD eradication a desirable goal in CLL?
Moreno C; Ritgen M; Rawstron A
Best Pract Res Clin Haematol; 2010 Mar; 23(1):97-107. PubMed ID: 20620974
[TBL] [Abstract][Full Text] [Related]
20. The Evolution of Targeted Therapies in Chronic Lymphocytic Leukaemia.
Gianfelici V; Levato L; Molica S
Curr Hematol Malig Rep; 2020 Aug; 15(4):343-349. PubMed ID: 32500413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
